



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 21, 2012, November 23, 2015

XGEVA® (denosumab)

LENGTH OF AUTHORIZATION: Up to six months

REVIEW CRITERIA:

- Patient must be ≥ 18 years old.
- **CONFIRMATION OF ONE OF THE FOLLOWING DIAGNOSES:**
 - Bone metastases from solid tumors confirmed by progress notes or medical records.
 - Giant Cell Tumor of the bone that is unresectable or resection will likely cause severe morbidity.
 - Hypercalcemia of malignancy refractory to bisphosphonate therapy.

DOSING & ADMINISTRATION:

Bone metastases from solid tumors: 120 mg every 4 weeks as a subcutaneous injection in the upper arm, upper thigh, or abdomen.

Giant Cell Tumor of Bone and Hypercalcemia of Malignancy: 120 mg given subcutaneously in the upper arm, upper thigh or abdomen on days 1, 8 and 15 initially, then 120 mg subcutaneous every 4 weeks beginning on day 29.